Atherectomy in CLI

Robert M. Bersin, MD, MPH Swedish Medical Center Seattle, Washington

What is Standalone Atherectomy?

- Atherectomy with no other therapy, or no other devices than adjunctive PTA?
 - Results of excisional atherectomy are equivalent with or without adjunctive PTA¹
 - Adjunctive PTA almost always performed following laser atherectomy (96%)² and orbital atherectomy (100%)³
 - Therefore, we consider atherectomy +/- PTA a standalone procedure

²Laird J et al *J Endovasc Ther* 2006; 13(1): 1-11

³Shammas NW et al *J Endovasc Ther* 2012; 19(4): 480-488

DEFINITIVE LE 180-day Patency

Device success (≤ 30% DS) was achieved with atherectomy alone in 540 lesions (75%)

% Diameter Stenosis ≤ 30% Following Plaque Excision

% Diameter Stenosis > 30% Following Plaque Excision

Stand-Alone SilverHawk/ TurboHawk Post-PE Stenosis: 18.2%
Mean Lesion Length: 6.7 cm
N = 412 lesions

100 0 0

180-Day Patency: 96.6%

Post-PE Stenosis: 36.3%

Mean Lesion Length: 9.2 cm

N = 35 lesions

180-Day Patency: 88.9%

SilverHawk/ TurboHawk + Adjunctive Therapy * Post-PE Stenosis: 19.8% Post-Adjunt. Stenosis:11.7% Mean Lesion Length: 6.9 cm

180-Day Patency:

97.0%

Post-PE Stenosis: 43.5%

Post-Adjunct. Stenosis: 22.9% Mean Lesion Length: 10.0 cm


N = 142 lesions


180-Day Patency: 93.9%

[&]quot;adjunctive therapy does not significantly impact 6 month patency"


Standalone Atherectomy

- Anatomic considerations
 - Common femoral artery
 - Popliteal artery
 - Graft anastomoses
 - TASC II C/D tibial-peroneal occlusions
- Clinical considerations
 - Bleeding disorders
 - Metal allergies










September 1, 2010



CXI and MiracleBros



LSC TurboHawk



LXC TurboHawk

September 1, 2010



September 1, 2010

DEFINITIVE LE 12-month Primary Patency

Subgroup	Claudicants (n=743)		CLI (n=279)	
	Patency (PSVR ≤ 2.4)	Lesion Length (cm)	Patency (PSVR ≤ 2.4)	Lesion Length (cm)
All (n=1022)	78%	7.5	71%	7.2
Lesion type				
Stenoses (n=806)	81%	6.7	73%	5.8
Occlusions (n=211) Lesion Location	64%	11.1	66%	10.3
SFA (n=671)	75%	8.1	68%	8.6
Popliteal (n=162)	77%	6.0	68%	5.4
Infrapopliteal (n=189)	90%	5.5	78%	6.0

McKinsey JF et al JACC Cardiovasc Interv 2014; 7(8): 923-933




September 1, 2010




January 30, 2012

DEFINITIVE LE CLI Patency and Limb Salvage



McKinsey JF et al JACC Cardiovasc Interv 2014; 7(8): 923-33.

Excimer Laser for CLI





Pre-intervention



Vitesse COS



6-months

LACI-2 CLI Trial 6-Mo Results


(N=145 pts/155 limbs)

- Mean lesion length 16.2 cm
- Infra-popliteal lesions comprised 41%
- Adjunctive stenting rate 45% (61% ATK and 16% BTK)
- Re-intervention rate 15%, bypass rate 2%
- Major amputation rate 7%
- Is an indicated therapy for CLI, but as a standalone therapy mainly for BTK lesions

Calcified Tibial-Peroneal Disease




CSI Diamondback 360



Orbital Atherectomy

2.25 mm crown can achieve up to a 4.5 mm lumen


before after



70% SFA lesion < 10% residual




Calcified Tibial-Peroneal Disease




Peroneal 2.25 Classic Crown









CONFIRM Registry CLI (RC 4-6) Sub-Analysis

CLI patient demographics (Rutherford Class 4-6)			
Gender N=1320			
	n/N (100%)		
Female	558/1320 (42%)		
Male	762/1320 (58%)		
Age	N=1263		
	Mean ± SD (Range)		
	72.7 ± 11.2 (24.0 - 99.0)		
Smoker			
Current	341/1261 (27%)		
Previous but quit	574/1261 (46%)		
Never	346/1261 (27%)		
History of:			
Diabetes	914/1306 (70%)		
Insulin dependent	459/821 (56%)		
Coronary artery disease	907/1297 (70%)		
Renal Disease	553/1303 (42%)		
Hypertension	1213/1314 (92%)		
Hyperlipidemia	1074/1302 (82%)		

Event rates among CLI patients (Rutherford Class 4-6)			
	Total	Moderate to severely calcified lesions	
Dissection	126/1321 (9.5%)	105/1149 (9.1%)	
Flow-Limiting	16/1321 (1.2%)	13/1149 (1.1%)	
Non-Flow Limiting	61/1321 (4.6%)	51/1149 (4.4%)	
Unknown	49/1321 (3.7%)	41/1149 (3.6%)	
Perforation	11/1321 (0.8%)	10/1149 (0.9%)	
Slow Flow	74/1321 (5.6%)	66/1149 (5.7%)	
Closure	20/1321 (1.5%)	18/1149 (1.6%)	
Spasm	90/1321 (6.8%)	74/1149 (6.4%)	
Embolism	22/1028 (2.1%)	15/893 (1.7%)	
Thrombus	14/1028 (1.4%)	8/893 (0.9%)	

Das T et al J Am Coll Cardiol 2013; 62: B163

CALCIUM 360° Study Design

Prospective, multi-center CLI study

N=50

- Randomized (1:1)
- Calcified BTK lesions only



Rutherford Class	OAS + BA N = 25	BA ALONE N = 25	P Value
4 (Ischemic rest pain)	48%	48%	1.00
5 (Minor tissue loss)	44%	44%	
6 (Major tissue loss)	8%	8%	


Rutherford classes were similarly distributed between the two study arms (p=1.00)

CALCIUM 360° Lesion Characteristics

	ORBITAL ARM	BALLOON ARM
Number Lesions	30	35
Moderately or Severely Calcified (>50% of lesion)	93%	94%

100% Infrapopliteal Lesions

- Pop
- AT
- PT
- Peroneal
- Cross-Segment



^{*}Lesion location was similarly distributed between the two study arms.

Shammas NW et al *J Endovasc Ther* 2012; 19: 480-488

CALCIUM 360° 1-Year Results

	OAS + BA	BA ALONE	P Value
Mean Max Balloon Inflation	5.9 atm	9.4 atm	0.001
Dissections (≥ Type C)	3.4%	5.7%	NR
Embolization	0	2.8%	NR
Perforation	0	2.8%	NR
Procedural Success	93.1%	82.4%	0.27
Bail-out stenting	6.9%	14.3%	0.44
12 month Freedom from MAE	93.3%	57.9%	0.006
12 month Freedom from Amputation related to index procedure	100%	100%	NA
12 month Freedom from all cause mortality	100%	68.4%	0.01
12 month Freedom from TLR/TVR	93.3%	80.0%	0.14

Shammas NW et al *J Endovasc Ther* 2012; 19: 480-488

Conclusions

- Standalone excisional atherectomy is particularly useful in CLI patients with CFA or popliteal disease, and for infrainguinal stenoses generally <10 cm.
- Standalone laser atherectomy is particularly useful in CLI patients with longer (>10 cm) infrapopliteal stenoses and thrombotic occlusions. The need for adjunctive therapies is acceptable BTK but is high ATK.
- Standalone orbital atherectomy is particularly useful in CLI patients with moderately to heavily calcified BTK stenoses with a low need for adjunctive therapies.
- Jetstream and Phoenix atherectomy have not been well studied although may have use in CLI patients.